Lantheus to present data on PET imaging agents at SNM meeting

05/19/2010 | (free registration)

Lantheus Medical Imaging said it will present initial data from a Phase II trial of its myocardial perfusion PET imaging agent, flurpiridaz F-18, at the upcoming SNM meeting. The company also will present Phase I results on its LMI1195 cardiac neuronal PET imaging agent.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX